Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01772719 · OUTCOME

Progression Free Survival (PFS)

Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid · Source last updated 2019-11-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
At start of year 2 follow up on all surviving participants

What was measured

Study will estimate PFS when there is one year of follow up data for all surviving participants

Analysis population: Study was terminated and PI has left the institution. Sincere efforts were made to gather and report the data, however, no data is available for the study

Groups in this outcome

Simvastatin and Zoledronic Acid

Simvastatin and zoledronic acid: 1. Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy. 2\. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Simvastatin and Zoledronic Acid0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Study will estimate PFS when there is one year of follow up data for all surviving participants
groups
  1. description
    Simvastatin and zoledronic acid: 1. Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy. 2\. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly.
    id
    OG000
    title
    Simvastatin and Zoledronic Acid
population Description
Study was terminated and PI has left the institution. Sincere efforts were made to gather and report the data, however, no data is available for the study
reporting Status
POSTED
time Frame
At start of year 2 follow up on all surviving participants
title
Progression Free Survival (PFS)
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice